Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Strengthening proprietary IP portfolio and next-generation product development pipeline

KEY HIGHLIGHTS

• Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C.
• Patent protection being pursued at national and regional levels across key international markets
• Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development
• Expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities
• Aligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value

CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A., has acquired ownership of international patent application WO2025108566A1 from Cloudpharm P.C., and expands its nanotechnology investment initiatives.

Following the transfer, Cana Laboratories has initiated the process of pursuing patent protection at both national and regional levels in key international markets as part of the Company’s broader IP strategy.

The patent represents an important addition to Cosmos Health’s growing innovation portfolio and reflects the Company’s commitment to transforming advanced scientific discoveries into commercially viable healthcare solutions. The underlying technology originated from research activities combining early-stage discovery methodologies with advanced pharmaceutical development approaches.

PATENT & IP DETAILS

FIELD	DETAIL
Patent Application	WO2025108566A1
Transferor	Cloudpharm P.C.
Acquirer	Cana Laboratories S.A. (wholly owned subsidiary of Cosmos Health Inc.)
Filing Status	National & regional patent protection being pursued across key international markets
Manufacturing Platform	European GMP-licensed, EMA-certified (Cana Laboratories S.A.)
Product Scope	Pharmaceutical, Nutraceutical, OTC, Specialized Healthcare
Technology Origin	Early-stage discovery methodologies combined with advanced pharmaceutical development

Schreibe Deinen Kommentar